PATENT APPLICATION

RECEIVED

AUG 1 0 2001

Applicant(s): Treuheit, et al.

TECH CENTER 1600/2900

Serial No.:

•

Group Art Unit No.: 1655

09/709,704

areap and control 1000

Filed:

November 9, 2000

Examiner: B. Sisson

For:

PROCESS FOR CORRECTION OF A DISULFIDE

MISFOLD IN FC MOLECULES

Docket No.: A-584

AMENDMENT UNDER 37 CFR 1.121

UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action dated May 8, 2001, please amend the application under 37 CFR 1.53 as follows:

In the Claims

Please cancel Claims 3, 17 to 27, 29, and 31.

Remarks

In general. Claims 1 to 16, 28 and 30 are in the case. Claims 17 to 27, 29 and 31 have been canceled pursuant to the restriction requirement imposed by the Office Action dated May 8, 2001, and the Applicants reserve the right to pursue them in continuation or divisional applications. No claim has been added or amended.

Election. The Applicants elect Group I, drawn to the process of Claim 1 <u>et seq</u>. The Office Action further required an election of species. The Applicants elect the following, which affirms the provisional election by phone: a.(i.) comprising a pharmacologically active site; b.(iv.) IL-1 inhibitor; c.(i.) preparation in <u>E. coli</u>. Claims 1, 2, 4 to 7, 14, 15, 28, and 30 are readable on the elected species.

Sequence Rules Compliance. The Office Action in paragraph no. 6 alleged that the sequence failed to comply with the requirements of 37 CFR 1.821 through 1.825 and that the Office Action included an explanatory Notice to Comply thereto. The Applicants' own review of the sequence listing currently on file with the United States Patent and Trademark Office does not reveal any errors, using the error-checking tool downloaded from the Office's

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number:	EL360689886US	Date of Deposit: Au	ugust 7, 2001	
	being deposited with the United States Postal Se			
indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. Sherry St. Andrew				
Shern	y St. Andrew		X. Wally	treu)
Pr	inted Name		Signature	